SAN DIEGO, April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today ...

Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why HALO is downgraded to Hold.

Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed beginning in 2011 to protect its MDASE subcutaneous delivery ...

Last November, Merck petitioned the PTO to reconsider seven patents that were awarded to Halozyme, arguing they were overly board and should not have been granted.

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an FDA rejection dragged on, while Sanofi revealed an immune drug setback.

Merck disputes this, declaring that the enzyme it has used was developed independently from Halozyme. Merck said it was confident in its legal position on the matter.

The dispute with Halozyme Therapeutics occurs as Merck plans to sell a new injectable version of Keytruda that the company is betting will sustain a medicine that has accounted for nearly half of ...

Halozyme Therapeutics Inc. is suing the company over the new version, claiming in a lawsuit filed Thursday that Merck has infringed its intellectual property.

Halozyme expected Merck to obtain a commercial license for the intellectual property it is using, but Merck has failed to do so and instead plans to launch SC Keytruda while knowingly infringing ...

Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE ...